All studies
CompletedPhase II/IIIInterventional

A trial for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome

Acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) are serious blood cancers that mainly affect older adults. While standard chemotherapy is widely used, it can be tough on the body and does not always keep the cancer away for long. The AML18 trial looks at adding newer, targeted drugs to standard chemotherapy treatments to see if this improves outcomes. The researchers want to discover if these new medicine combinations can destroy more leukaemia cells with fewer or more manageable side effects. The study is mainly for people aged 60 and over who are well enough to receive intensive treatment. Taking part involves hospital visits for chemotherapy, regular blood tests, and health checks. By joining, participants help doctors learn how to tailor blood cancer treatments better, which could improve survival rates and future care across the NHS.

At a glance

Status
Completed
Phase
Phase II/III
Sponsor
Cardiff University (UK)
Enrolment target
1,600
Start
31 Oct 2013
Estimated completion
31 Dec 2022

What is this study about?

Acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) are conditions that affect bone marrow, the soft centre inside your bones where blood cells are made. In these illnesses, the body produces faulty, immature white blood cells that cannot fight off infections properly. As these abnormal cells build up, there is less room for healthy red blood cells and platelets. This can cause tiredness, bruising, and frequent infections. While treatments exist, finding effective options that are safe for older adults remains a major challenge in blood cancer care.

The AML18 trial explores whether adding newer, targeted medications to standard chemotherapy can help clear cancer cells more effectively. Targeted drugs work by attacking specific parts of cancer cells, which may stop them from growing or make chemotherapy work better. Doctors want to see if these new approaches can help people live longer, prevent the leukaemia from returning, and maintain a good daily quality of life.

Trials like this are essential because older bodies often process medicines differently, meaning treatments designed for younger patients might cause unwanted problems. By testing different combinations, researchers hope to establish clearer, safer, and more effective treatment paths for older adults across the UK. The knowledge gained from this trial could change standard NHS care for years to come.

Key takeaways

  • The trial tests new targeted drug combinations for older adults with AML or high-risk MDS.
  • It aims to improve remission rates and survival with manageable side effects.
  • Most participants are aged 60 and over and must be fit enough for intensive treatment.
  • Care involves hospital stays, blood checks, and long-term follow-up visits.
  • Taking part is completely voluntary, and you can stop at any time.

Who may be eligible?

This trial is designed mainly for adults aged 60 and over who have been newly diagnosed with acute myeloid leukaemia (AML) or a severe form of myelodysplastic syndrome (MDS). In certain situations, people under 60 may join if other trials are not suitable for them. Doctors will confirm the exact type of blood condition using standard bone marrow and blood tests.

To join, participants need to be active enough to manage everyday tasks and self-care, although they do not need to be in perfect health. A doctor will check that your kidneys and other main organs are working well enough to safely receive intensive cancer therapy. People with a specific type of leukaemia called acute promyelocytic leukaemia (APL) cannot join, as this condition requires a different, specialised treatment.

Safety is a top priority. Because cancer medicines can harm an unborn baby, both men and women taking part must agree to use reliable contraception during treatment and for a set number of months afterwards. Your hospital team will review your full medical history, current medicines, and general fitness before confirming if this study is an option for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I have been diagnosed with acute myeloid leukaemia (AML) or high-risk MDS.
  2. I am aged 60 or older (or under 60 and not eligible for other trials).
  3. I do not have acute promyelocytic leukaemia (APL).
  4. I am generally well enough to walk around and manage my own personal care.
  5. I am willing to use reliable contraception if pregnancy is possible.
Answer every question to see your result.

What does participation involve?

Taking part involves receiving intensive chemotherapy alongside study medicines through a drip or as tablets. Treatment is divided into blocks called cycles, each lasting several weeks. You will spend time staying in hospital, especially during the early stages of chemotherapy when your body is resting and recovering from treatment.

Throughout the study, you will have regular blood tests, physical examinations, and occasional bone marrow checks to see how well the cancer is responding. Doctors will also check for any side effects and monitor your heart and kidney function. Between hospital stays, you will attend outpatient appointments to ensure your recovery is on track.

After your treatment cycles finish, you will enter a follow-up phase. The medical team will check on your health every few months through routine clinic visits and blood tests. In total, your participation and monitoring will last for several years, helping researchers gather long-term evidence on how well the treatments work.

Potential risks and benefits

A potential benefit of joining this study is receiving newer, targeted therapies that might work better against your leukaemia than standard treatment alone. You will also receive very close, expert medical supervision throughout. However, new treatments carry potential risks, such as stronger side effects, unusual reactions, or the possibility that the trial drug may not be more effective than standard care. Common side effects of blood cancer therapies include fatigue, sickness, and a higher risk of infections. Joining is entirely your choice, and you are free to leave the trial at any time without your regular NHS care or relationship with your medical team being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • Nottingham City Hospital
    City only
    Nottingham, England

Common questions

Do I have to pay to take part in this trial?

No, all study drugs, extra tests, and hospital care related to the trial are provided free of charge through the NHS.

Will I definitely receive the new study drugs?

Not necessarily. This is a randomised trial, which means a computer decides whether you receive standard chemotherapy or chemotherapy combined with a newer drug, giving each group equal and fair comparison.

Can I leave the study if I change my mind?

Yes, you can leave the study at any point without giving a reason. Your doctors will continue to give you the best available standard treatment.

How long will I have to stay in hospital?

Intensive chemotherapy usually requires a hospital stay of a few weeks per cycle, until your blood counts recover and the risk of infection drops.

Why is contraception required for older patients?

Some trial drugs can cause severe harm to developing babies. Contraception is required if you or your partner could potentially become pregnant, to ensure complete safety.

How to find out more

Nigel Russell

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.